in vivo News and Research

RSS

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecule compounds that target P2X3 receptors, today announced preclinical in vivo results demonstrating that an investigational P2X3 receptor antagonist reduced experimentally induced bladder hyperactivity.

26 Aug 2010

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Alnylam Pharmaceuticals, Inc.,a leading RNAi therapeutics company, announced today that it will make a total of 16 oral presentations at the American Chemical Society (ACS) Fall 2010 240th National Meeting & Exposition being held in Boston, Mass. from August 22-26, 2010.

24 Aug 2010

APC dysfunction prevents synapse function required for learning, memory: Study

A clue to the causes of autism and mental retardation lies in the synapse, the tiny intercellular junction that rapidly transfers information from one neuron to the next. According to neuroscientists at Tufts University School of Medicine, with students from the Sackler School of Graduate Biomedical Sciences at Tufts, a protein called APC plays a key role in synapse maturation, and APC dysfunction prevents the synapse function required for typical learning and memory.

23 Aug 2010

Scientists identify compound to treat Chagas' disease

A new compound may offer an effective drug candidate against the deadly tropical infection, Chagas' disease say researchers from Brazil. They report their findings in the August 2010 issue of the journal Antimicrobial Agents and Chemotherapy.

21 Aug 2010

Cetero Research expands Clinical Dermatology and Transdermal Delivery System services

Cetero Research, the leading early stage contract research organization (CRO), today announced the expansion of multiple Clinical Dermatology and Transdermal Delivery System (TDDS) services to four Cetero clinical facilities.

20 Aug 2010

Cluster-coated implant strengthens attachment of joint-replacement implant with bone

Researchers have developed an improved coating technique that could strengthen the connection between titanium joint-replacement implants and a patients' own bone. The stronger connection created by manipulating signals the body's own cells use to encourage growth could allow the implants to last longer.

19 Aug 2010

Zebrafish-yeast approach for studying copper deficiency, complex multifactorial diseases

Copper deficiency diseases can be devastating. Symptoms can range from crippling neurological degeneration in Menkes disease ,a classic copper deficiency disease to brittle bones, anaemia and defective skin pigmentation in gastric bypass patients. Unfortunately, very little is known about how the body uses this essential nutrient. Knowing that melanocytes (the cells that give rise to hair, skin and eye pigmentation) are dramatically affected by the effects of copper deficiency, Elizabeth Patton from the University of Edinburgh, UK, and other colleagues from UK and US based labs decided to find out how melanocytes metabolise copper.

17 Aug 2010

Researchers develop method to predict lifetime of implants

Extra-hard coatings made from diamond-like carbon (DLC) extend the operating lifetime of tools and components. In artificial joints, however, these coatings often fail because they detach. Empa researchers found out why - and developed methods to both make the interface between the DLC layer and the metal underneath corrosion-resistant and to predict the lifetime of the implants.

16 Aug 2010

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

Mercator Therapeutics, the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs, today announced the signing of a license agreement with The University of Texas MD Anderson Cancer Center and the closing of a $2.0 million seed round.

13 Aug 2010

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.

12 Aug 2010

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Amorfix Life Sciences, a product development company focused on misfolded protein diseases, today announced its operational and financial results for the three months ended June 30, 2010.

12 Aug 2010

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Evotec AG today reported financial results and corporate updates for the first half of 2010.

12 Aug 2010

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the second quarter ended June 30, 2010.

11 Aug 2010

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the second quarter ended June 30, 2010.

11 Aug 2010

Quick-Med develops new NIMBUS Advanced Active prototype wound dressing

Quick-Med Technologies, Inc. announced today the development of a new prototype wound dressing, NIMBUS® Advanced Active, developed as part of ongoing research currently being funded by the U.S. Army Medical Research and Material Command under a $900,000 Small Business Innovation Research (SBIR) grant. NIMBUS was competitively selected by the U.S. Army for evaluation in the healing of vesicant injuries, and this new dressing is the first "active" wound healing product developed by Quick-Med.

10 Aug 2010

Epitherix identifies potent and selective multiple chemical scaffolds against colorectal carcinoma

Epitherix, LLC, a privately held company focused on the discovery and development of novel Wnt pathway small molecule inhibitors for epithelial and leukemic cancers, today announced that it has identified multiple chemical scaffolds that are potent and selective against colorectal carcinoma. "We're very encouraged by our in vitro and in vivo data, especially considering the difficulty in drugging this pathway to date," said Dr. Osman Kibar, CEO of Epitherix.

10 Aug 2010

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.

10 Aug 2010

Scientific paper explains impact of visual cycle modulation in neurovascular retinopathy

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that a scientific paper co-authored by Ryo Kubota, M.D., Ph.D., chairman, president and chief executive officer of Acucela, has been published in Experimental Eye Research. The paper, "Visual Cycle Modulation in Neurovascular Retinopathy" was also co-authored by scientists from Children's Hospital and Harvard Medical School in Boston and demonstrates for the first time the impact of treatment with a visual cycle modulator (VCM) on retinopathy in an immature eye.

10 Aug 2010

Scientist develops nano-methods to destroy tumors with fewer side effects

Though a valuable weapon against cancerous tumors, radiation therapy often harms healthy tissue as it tries to kill malignant cells. Now, Prof. Israel Gannot of Tel Aviv University's Department of Biomedical Engineering is developing a new way to destroy tumors with fewer side effects and minimal damage to surrounding tissue.

10 Aug 2010

New insights into development and applications of pharmacogenomics in psychiatry

In recent years, there have been major developments in the fields of pharmacogenetics and pharmacogenomics, with the potential to make drug treatments in psychiatric medicine more effective. However, improvements in drug efficacy and tolerability, as well as finding the optimal dosage, can only be realized if in vivo mechanisms of drug action and ADME (absorption, distribution, metabolism, excretion) processes (pharmacokinetics) of psychopharmacological agents are better understood.

5 Aug 2010

in vivo News and Research

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

APC dysfunction prevents synapse function required for learning, memory: Study

Scientists identify compound to treat Chagas' disease

Cetero Research expands Clinical Dermatology and Transdermal Delivery System services

Cluster-coated implant strengthens attachment of joint-replacement implant with bone

Zebrafish-yeast approach for studying copper deficiency, complex multifactorial diseases

Researchers develop method to predict lifetime of implants

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

Quick-Med develops new NIMBUS Advanced Active prototype wound dressing

Epitherix identifies potent and selective multiple chemical scaffolds against colorectal carcinoma

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Scientific paper explains impact of visual cycle modulation in neurovascular retinopathy

Scientist develops nano-methods to destroy tumors with fewer side effects

New insights into development and applications of pharmacogenomics in psychiatry

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News